Reported Earlier, Celldex Therapeutics Announces Data From Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction In Itch And Skin Clearing With Single Dose 3.0 Mg/Kg Barzolvolimab
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics has announced data from its Phase 1b study on Prurigo Nodularis, demonstrating a significant reduction in itch and skin clearing with a single dose of 3.0 mg/kg Barzolvolimab.
November 06, 2023 | 6:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from Celldex Therapeutics' Phase 1b study could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that the results are from a Phase 1b study, the impact might not be as significant as results from a later-stage trial, but it still indicates progress in the company's pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100